Cenobamate Drug Resistant Epilepsy: Review Findings in Adults and Children

What was studied

This systematic review and meta-analysis combined 36 studies of cenobamate for drug-resistant epilepsy, meaning seizures that continue despite medication treatment. Researchers searched four research databases for studies published through May 2026.

The review included 22 studies involving 6,256 adults, 6 studies involving 256 children, and 8 mixed-age studies involving 451 people. The mixed-age studies did not report separate results for adults and children, so they contributed only to the all-age analysis.

Researchers combined results for seizure reduction, seizure freedom, adverse events, and serious adverse events. They used a random-effects model because substantial differences among studies were anticipated and observed. Most studies were retrospective observational studies, meaning they looked back at existing patient information.

What they found

Adults: The pooled responder proportion (at least a 50% reduction in seizures) was 0.65 (95% confidence interval [CI]: 0.58–0.71; 21 studies, 3,871 people). The seizure freedom rate was 0.15 (CI: 0.10–0.21; 21 studies, 3,963 people). The incidence of adverse events was 0.63 (CI: 0.51–0.74; 17 studies, 3,611 people). The pooled serious adverse event estimate was 0.00 (CI: 0.00–0.02; 19 studies, 3,487 people).

Children: The preliminary responder proportion was 0.60 (CI: 0.39–0.78; 6 studies, 256 children). The preliminary seizure freedom rate was 0.20 (CI: 0.15–0.26; 4 studies, 212 children). The preliminary incidence of adverse events was 0.48 (CI: 0.42–0.55; 5 studies, 236 children), and the preliminary incidence of serious adverse events was 0.03 (CI: 0.01–0.12; 4 studies, 63 children).

All ages combined: The responder proportion was 0.63 (CI: 0.58–0.68; 35 studies, 4,578 people). The seizure freedom rate was 0.15 (CI: 0.11–0.19; 32 studies, 4,392 people). The incidence of adverse events was 0.62 (CI: 0.53–0.69; 29 studies, 4,253 people). The pooled serious adverse event estimate was 0.00 (CI: 0.00–0.02; 30 studies, 3,767 people).

The child and adult estimates were numerically similar, but this was an indirect comparison across different studies. A pooled estimate reported as 0.00 does not establish that serious adverse events never occur.

Limits of the evidence

Most studies were retrospective observational studies. These pooled estimates alone cannot establish how much benefit cenobamate caused or how it compares with other treatments. Results differed substantially across studies.

The evidence in children was much smaller than in adults, especially for serious adverse events, which were assessed in only 63 children. The review does not establish that effectiveness or safety is the same in children and adults. The abstract does not give treatment doses, follow-up lengths, how long seizure freedom lasted, specific adverse events, or the results of the risk-of-bias assessments.

For families and caregivers

The results suggest that many people with difficult-to-treat epilepsy experienced fewer seizures while taking cenobamate, and some had no seizures during the periods studied. Adverse events were also common. The abstract describes cenobamate as FDA-approved for adults with focal-onset seizures; the findings in children remain preliminary and do not establish the same level of evidence for pediatric use.

What to watch next

Further prospective studies—following children forward in time—are needed to better assess cenobamate’s effectiveness and safety in pediatric patients.

Terms in this summary

Cenobamate

An anti-seizure medication, also called CNB.

Drug-resistant epilepsy

Epilepsy in which seizures continue despite medication treatment.

Focal-onset seizure

A seizure that starts in one area of the brain.

Meta-analysis

A method that combines results from several studies to calculate an overall estimate.

Responder

In this review, someone whose seizure frequency fell by at least 50%.

Confidence interval

A range that describes uncertainty around an estimate; wider ranges generally mean less precision.

Adverse event

An unwanted health problem reported during treatment, which is not necessarily caused by the treatment.

Serious adverse event

A health problem with a serious outcome, such as hospitalization or a threat to life.